A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma

NCT06653322 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma With Eosinophilic Phenotype

Interventions

DRUG: HR-1703
DRUG: Placebo

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd